10/570229 IAP6 Rec'd PCT/PT0 28 FEB 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Ronnie Maxwell LAWRENCE International Application No.: PCT/EP2004/009819

International Filing Date: September 2, 2004

For: PROCESS FOR THE PREPARATION OF (18, 4R)-CIS-4-[2-AMINO-6-CHLORO-9H-PURIN-9-YL]-2-CYCLOPENTENE-1-METHANOL

Commissioner for Patents

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

[X] Copies of the references are enclosed	
[] Copies of the references were submitted in parent application	Serial No.
(37 CFR 1.98(d))	

[X] A copy of the International Search Report which issued on International Application No. PCT/EP204/009819 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
 - OR

 [] The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. [] The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
 - (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311, whichever occurs first.

Express Mail Label No.: EV332131204US

Alexandria, VA 22313-1450 on the date shown above.

atty Wilson

Atty. Docket No. PB60476USw

ſΊ

C.

JAPS Rec'd PCT/PTO 28 FEB 2006 Applicant hereby certifies that each item of information contained in this Information

	Discousire Statement was creed in a communication from a folergin parent office in a counterpart foreign application not more than three months prior to the filing of this statement.							
[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § $1.97(c)$ (\$180.00).							
[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.							
In acco	ordance with the requirements of 37 CFR 1.97(d):							
[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]							
[]	Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and							

The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392. [] A duplicate copy of this paper is attached.

Respectfully Submitted,

Karen L. Prus Attorney of Record Registration No. 39,337

28, 2000

Customer No. 233430 GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

Telephone: (919) 483-2192 Facsimile: (919) 483-7988

[]

LAPS ROC'd PCT/PTO 28 FEB 2006 Page 1 of 1

FORM PTO-1449			INT'L FILING NO. PCT/EP2004/009819							
		DISCLOSURE ST	ATEMENT		INT'L FILING NO.			September 2, 2004		
	INTO ROTATION DISCLOSURE STATEMENT			APPLICANT		Lawrence				
					GROUP					
EXAMINER				10/5	70229					
						OCKETNO	DD 60 476	PB60476USw		
ATTORNEY DOCKET NO. PB60476USW U.S. PATENT DOCUMENTS										
U.S. FATENT BOCUMENTS Filing Date										
Examiner Initials		Patent Number	Issue Date	Name		Class	Subclass If Appropriate			
FOREIGN PATENT DOCUMENTS										
		Document Number	Publication Date	Country		Class	Subclass	Translation Yes No		
	1.	0325460	10/21/1992	EP						
	2.	0434450	7/7/1999	EP						
	3.	0628044	12/14/1994	EP				***************************************		
	4	0741710	11/13/1006	ED						
	5.	WO95/21161	8/10/1995	PCT						
	6.	WO98/52949	11/26/1998	PCT						
	7.	WO99/19327	4/22/1999	PCT						
	8	WO00/10327	4/6/2000	PCT						
		OTHER DOCUM	IENTS (Includi	g Author.	Title, Journal-Da	te. Page Num	her. Etc.)			
	9.									
	10.		ERGE et al., Pharmaceutical Salts, J. of Pharm. Sci. 66(1):1-19 (1977). ALUGE et al., An Efficient, Scalable synthesis of the HIV Reverse Transcriptase Inhibitor Ziagen®							
					ic Acids 19:297-32					
	11.	FLEISHER et al.,	Improved oral d	rug delivery	: solubility limitati	ions overcome	by the use of	prodrugs,		
		Advanced Drug D					-			
	12.	HIGUCHI and ST		s as Novel 1	Drug Delivery Syst	ems, ACS Syr	nposium Serie	es 14, Amer.		
		Chem. Soc., (Sept	t. 1974).							
	13.				eries of Purine Der	rivatives and tl	heir Anti-Cycl	in-Dependent		
		Kinase Activities,								
	14.				ce in Zucker Fatty			n of the		
	-				hiazolidide, Diabe					
	15.				tivity of Carbocyc		ıydro-2',3'-di	deoxy 2,6-		
		Disubstituted Pur	me Nucleosides,	J. Med. Che	m. 33:17-21 (1990)).				
	-									
	-			•						
EVANDED						I numm	201/2122			
EXAMINER /Mark Berch/ (09/23/2008) DATE CONSIDERED										
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through										
citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.										

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/